A phase II study of concurrent accelerated hyperfractionated radiotherapy and carboplatin/oral etoposide for elderly patients with stage III non-small-cell lung cancer

International Journal of Radiation Oncology Biology Physics

Volumn 44, Issue 2, 1999, Pages 343-348

  Jeremic, Branislav ^a   Shibamoto, Yuta ^d   Milicic, Biljana ^a   Milisavljevic, Slobodan ^b   Nikolic, Nebojsa ^a   Dagovic, Aleksandar ^a   Aleksandrovic, Jasna ^a   Radosavljevic Asic, Gordana ^c  

^a Department of Oncology ^*  (Serbia)

^b University Hospital   (Serbia)

^c Clinical Center   (Serbia)

^d KYOTO UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Nonsmall cell lung cancer; Radiation therapy; Stage III

Indexed keywords

CARBOPLATIN; ETOPOSIDE;

AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ESOPHAGITIS; FEMALE; HEMATOLOGIC DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIMODALITY CANCER THERAPY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RESPIRATORY TRACT DISEASE; TREATMENT OUTCOME;

EID: 0032961620     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(99)00006-1     Document Type: Article

References (41)

1. Yank R., Rise L.G. Cancer in the aged An epidemiologic perspective on treatment issues . Cancer. 68:1991;2502-2510.
2. Petrovich Z., Stanley K., Cox J., et al. Radiotherapy and the management of locally advanced lung cancer of all cell types Final report of randomized trial . Cancer. 48:1981;1335-1340.
3. Crocker J., Prosnitz L. Radiation therapy of the elderly. Clin Geriatr Med. 3:1987;473-481.
4. Pignon T., Gregor A., Schaake Koning C., et al. Age has no impact on acute and late toxicity of curative thoracic radiotherapy. Radiother Oncol. 46:1998;239-248.
5. Choi N.C., Doucette J.A. Improved survival of patients with unresectable non-small cell bronchogenic carcinoma by an innovated high-dose en bloc radiotherapeutic approach. Cancer. 48:1981;101-109.
6. Perez C.A., Pajak T.F., Rubin P., et al. Long term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer. 59:1987;1874-1881.
7. Cox J.D., Azarnia N., Byhardt R.W., et al. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 to 79.2 Gy - possible survival benefit with > 69.6 Gy in favorable patients with Radiation Therapy Oncology group stage III nonsmall cell lung carcinoma. Report of Radiation Therapy Oncology Group 83-11. J Clin Oncol. 8:1990;1543-1555.
8. Saunders M., Dische S., Barrett A., et al. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer A randomized multicentre trial . Lancet. 350:1997;161-165.
9. King S.C., Acker J.C., Kussin P.S., et al. High-dose, hyperfractionated, accelerated radiotherapy using a concurrent boost for the treatment of nonsmall cell lung cancer Unusual toxicity and promising early results . Int J Radiat Oncol Biol Phys. 36:1996;593-599.
10. Schaake-Konig C., van der Bogaert W., Dalesio O., et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med. 326:1992;524-530.
11. Lee J.S., Scott C., Komaki R., et al. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer Radiation Therapy Oncology Group protocol 91-06 . J Clin Oncol. 14:1996;1055-1064.
12. Jeremic B., Shibamoto Y., Acimovic L., et al. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol. 13:1995;452-458.
13. Jeremic B., Shibamoto Y., Acimovic L., et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer A randomized study . J Clin Oncol. 14:1996;1065-1070.
14. Dillman R.O., Herndon J., Seagren S.L., et al. Improved survival in stage III non-small-cell lung cancer 7-year follow-up of cancer and leukemia group B (CALGB) 8433 trial . J Natl Cancer Inst. 88:1997;1210-1215.
15. Komaki R., Scott C.B., Sause W.T., et al. Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer Failure patterns by cell type in RTOG 88-08/ECOG 4588 . Int J Radiat Oncol Biol Phys. 39:1997;537-544.
16. Albain K.S., Rusch V.W., Crowley J.J., et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer Mature results of Southwest Oncology Group phase II study 8805 . J Clin Oncol. 13:1995;1880-1892.
17. Choi N.C., Carey R.W., Daly W., et al. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer. J Clin Oncol. 15:1997;712-722.
18. Wilson G.D., McNally N.J., Dische S., et al. Measurement of cell kinetics in human tumors in vivo using bromodeoxyuridine incorporation and flow cytometry. Br J Cancer. 58:1988;423-431.
19. Shibamoto Y., Ike O., Mizuno H., et al. Proliferative activity and micronucleus frequency after radiation of lung cancer cells as assessed by the cytokinesis-block method and their relationship to clinical outcome. Clin Cancer Res. 4:1998;677-682.
20. Kerr K.M., Lamb D. Actual growth rate and tumor cell proliferation in human pulmonary neoplasms. Br J Cancer. 50:1984;343-349.
21. Mirimanoff R.O., Moro D., Bolla M., et al. Alternating radiotherapy and chemotherapy for inoperable stage III non-small-cell lung cancer Long-term results of two phase II GOTHA trials . Int J Radiat Oncol Biol Phys. 42:1998;487-494.
22. Ball D., Bishop J., Smith J., et al. A phase III study of accelerated radiotherapy with and without carboplatin in nonsmall cell lung cancer An interim toxicity analysis of the first 100 patients . Int J Radiat Oncol Biol Phys. 31:1995;267-272.
23. Withers H.R. Biologic basis for altered fractionation schemes. Cancer. 55:1985;2086-2095.
24. Bonomi P., Finkelstein D.M., Ruckdeschel J.C., et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer A study of the Eastern Cooperative Oncology Group . J Clin Oncol. 7:1989;1602-1613.
25. Dombernowsky P., Nissen N.I. Schedule dependency of the antileukemic activity of the podophyllotoxin-derivative VP-16-213 (NSC-141540) in L1210 leukemia. Acta Path Microb Scand (A). 81:1973;715-724.
26. Clark P.I., Slevin M.L. The clinical pharmacology of etoposide and teniposide. Clin Pharmacokinet. 12:1987;223-252.
27. Hainsworth J.D., Johnson D.H., Frazier S.R., et al. Chronic daily administration of oral etoposide A phase I trial . J Clin Oncol. 7:1989;396-401.
28. Pedersen A.G., Hansen H.H. Etoposide (VP-16) in the treatment of lung cancer. Cancer Treat Rev. 10:1983;245-264.
29. Ruckdeschel J.C. Etoposide in the management of non-small cell lung cancer. Cancer. 67:(Suppl. 1):1991;250-253.
30. Jeremic B., Acimovic L., Matovic M. Carboplatin and etoposide in patients with advanced gastric cancer. J Chemother. 5:1993;266-270.
31. Jeremic B., Acimovic L., Mijatovic L. Carboplatin and etoposide in advanced colorectal carcinoma A phase II study . Cancer. 71:1993;2706-2708.
32. Jeremic B., Grujicic D., Jevremovic S., et al. Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma A phase II study . J Clin Oncol. 10:1992;1074-1077.
33. Klastersky J., Sculier J.P., Lacroix H., et al. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer European Organization for Research and Treatment of Cancer protocol 07861 . J Clin Oncol. 8:1990;1556-1562.
34. Miller A.B., Hoogstraten B., Staquet M., et al. Reporting results of cancer treatment. Cancer. 47:1981;207-214.
35. Cox J.D., Stetz J., Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for the Treatment and Research of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 31:1995;1341-1346.
36. Lee J.S., Komaki R., Fossel F.V., et al. A pilot trial of hyperfractionated thoracic radiation therapy with concurrent cisplatin and oral etoposide for locally advanced inoperable non-small-cell lung cancer A 5-year follow-up report . Int J Radiat Oncol Biol Phys. 42:1998;479-486.
37. Byhardt R.W., Scott C., Sause W.T., et al. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. Int J Radiat Oncol Biol Phys. 42:1998;469-478.
38. Lau D.H., Crowley J.J., Gandara D.R., et al. Southwest Oncology Group phase II trial of concurrent carboplatin, etoposide, and radiation for poor-risk stage III non-small-cell lung cancer. J Clin Oncol 16; 1998;3078-3081.
39. Bardet E., Riviere A., Charloux A., et al. A phase II trial of radiochemotherapy with daily carboplatin after induction chemotherapy (carboplatin and etoposide), in locally advanced nonsmall-cell lung cancer Final analysis . Int J Radiat Oncol Biol Phys. 38:1997;163-168.
40. Atagi S., Furuse K., Kawahara M., et al. Phase II trial of daily low-dose carboplatin (CBDCA) and radiotherapy (RT) in elderly patients with unresectable locally advanced non-small cell lung cancer (NSCLC). Lung Cancer. 18:(Suppl. 1):1997;138.
41. 2 in patients with advanced non small cell lung cancer (NSCLC): Is there an impact of the reached area under the curve (AUC) on response, survival, and hematological toxicity? Lung Cancer 1997;18(Suppl. 1):43-44.